Tempus AI Gains 0.91% as $250M Volume Ranks 460th Amid Earnings Pressures

Market Snapshot

Tempus AI (TEM) rose 0.91% to $49.98 on March 13, 2026, with a trading volume of $250 million, ranking 460th in market activity for the day. The stock closed at $49.98 at 4:00 PM EDT, then edged higher to $50.00 in after-hours trading. The company’s market capitalization stood at $8.935 billion, with a 52-week range of $36.22 to $104.32. Despite the modest gain, the stock faces structural challenges, including a trailing twelve-month (TTM) earnings per share (EPS) of -$1.41 and no dividend yield.

Key Drivers

The stock’s performance on March 13 reflects a mix of cautious optimism and underlying financial pressures. Recent quarterly results for Q3 2025 showed Tempus AI outperformed revenue forecasts by $5.5 million (1.67%) and beat EPS estimates by $0.07, despite reporting a loss of $0.11 per share. This marked the company’s first positive adjusted EBITDA, driven by 33% growth in genomics and 37% expansion in hereditary testing segments. The acquisition of Paige.AI, a digital pathology firm, has bolstered its technical capabilities, aligning with CEO Eric Lefkofsky’s long-term vision of 25% annual growth through 2035.

However, broader financial metrics remain concerning. For FY 2025, operating income declined to -$50.8 million, and net income margin worsened to -14.75%. The company’s reliance on R&D and selling, general, and administrative (SG&A) expenses—$61.4 million and $111.4 million, respectively, in Q3 2025—highlights ongoing cost pressures. Despite these challenges, five analysts revised earnings forecasts upward in recent months, signaling potential for improved performance as the Paige.AI integration progresses.

Analyst sentiment is split, with 12 “Buy” or “Outperform” ratings and six “Hold” recommendations as of early March 2026. Price targets range from $59 to $105, with a median of $80. Mizuho and H.C. Wainwright recently initiated coverage at $100 and $95, respectively, citing the company’s AI-driven healthcare positioning. Yet, risks persist: regulatory hurdles for new product submissions, integration complexities from the Paige.AI acquisition, and intense competition in the genomics sector.

The stock’s 0.91% gain contrasts with its historical volatility, as evidenced by a 4.76% after-hours drop following Q3 2025 earnings despite beating forecasts. This suggests market skepticism about Tempus AI’s ability to sustain profitability. While the company’s strategic bets on AI and digital pathology could drive long-term value, near-term earnings forecasts remain negative, with all 2026 estimates projecting losses. Investors are likely weighing these factors against the potential for transformative growth in the AI healthcare sector, where Tempus AI’s market cap implies a 62x forward P/E ratio based on 2026 revenue projections.

Strategic Outlook

Looking ahead, Tempus AI’s trajectory hinges on three key variables. First, the successful integration of Paige.AI must translate into measurable revenue synergies, particularly in oncology and diagnostic imaging. Second, the company’s ability to reduce SG&A expenses—currently accounting for 47% of revenue—will be critical to improving margins. Third, regulatory approvals for new AI-driven tools could differentiate Tempus AI from competitors, but delays or rejections could stifle momentum. With a May 5, 2026, earnings date on the horizon, the market will scrutinize progress on these fronts to determine whether the stock can sustain its recent modest gains or face renewed downward pressure.